drugset / Trial / NCT06998004

A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults

NCT06998004 ↗

Phase 1 Completed 112 enrolled AstriVax Therapeutics
RandomizedSequentialQuadruple-blindPrevention

Summary

The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of AVX70120 and of AVX70481 in healthy participants.

Timeline

Start
2024-06-16
Primary completion
2026-01-26
Completion
2026-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject AVX70120 Vaccine — —
Subject AVX70481 Vaccine — —

Indications